Peptide Research News - PharmaGap In Vivo Study Results Include Indication of 80% to 88% Reduction in ... - MarketWatch (press release)

PharmaGap In Vivo Study Results Include Indication of 80% to 88% Reduction in ... - MarketWatch (press release)

PharmaGap In Vivo Study Results Include Indication of 80% to 88% Reduction in ... MarketWatch (press release) Commenting on these results, Dr. Ken Sokoll, Vice President Clinical Development and Chief Operating Officer for PharmaGap, said "The findings from this study demonstrate that repeat administration of peptide loaded liposomes is tolerable at doses ... and more »

Click Here to read the entire article...